Chronoscale Holdings Corp quarterly report, Q3 FY2013

Filing summary

Entity and period: The supplied filing is for PN Med Group Inc., not Chronoscale Holdings Corp. It is a Form 10-Q for the quarter ended December 31, 2012, covering the nine months since the company’s January 30, 2012 inception. The company describes itself as a development-stage medical-supplies distributor planning to serve customers in Chile, sourcing products from China. The financial statements are unaudited.

Financial results and position

  • Revenue: $0 for the three and nine months ended December 31, 2012, and $0 since inception.
  • Net loss: $1,777 for the quarter and $7,924 for the nine-month period, per the statements of operations; cumulative loss since inception was $12,581. The MD&A gives the nine-month loss as $7,929, which conflicts with the financial statements.
  • Expenses: Nine-month operating expenses were $7,924: professional fees $7,521, bank fees $316, and miscellaneous expenses $87. No income tax provision was recorded.
  • Cash and liquidity: Cash was $29,950 at December 31, 2012, versus $8,443 at March 31, 2012. Current liabilities were $18,531, including $17,781 owed to a shareholder and $750 of accrued expenses. Working capital was therefore $11,419; total assets were $29,950 and stockholders’ equity was $11,419.
  • Cash flows: The cash flow statement reports $11,674 used in operating activities and $33,181 provided by financing during the nine months, leaving a $21,507 increase in cash. There were no investing cash flows. Financing included $19,000 from stock issuance and $14,181 in additional shareholder loans.
  • Shareholder loan: The $17,781 balance is unsecured, non-interest-bearing, and due on demand. The company reports no bank credit lines or financing arrangements.
  • Equity: 5,950,000 common shares were outstanding at December 31, 2012, compared with 5,000,000 at March 31, 2012. The company sold 950,000 shares during the quarter for $19,000.

Changes, outlook, and risks

  • From March 31 to December 31, cash increased by $21,507, shareholder loans rose by $14,181, and stockholders’ equity increased from $343 to $11,419. The company had no revenue in the reported periods.
  • Management expects to need additional capital to sustain and expand operations, including to fund inventory, startup, and marketing costs. It anticipates seeking equity or debt financing but reports no specific financing plan or existing commitment. Further equity or convertible-debt issuance could dilute shareholders; financing may not be available on acceptable terms or at all.
  • The filing identifies substantial doubt about the company’s ability to continue as a going concern. Management says available funds and anticipated financing are expected to cover operations for the next three months, but also says additional funds will be needed within the next twelve months. There is no assurance that financing or commercial viability will be achieved.
  • Management concluded disclosure controls and procedures were not effective as of December 31, 2012. It reported no material change in internal control over financial reporting during the quarter.
  • An officer provided office services without charge and is not obligated to continue. The filing reports no material subsequent events and no known pending or threatened legal proceedings.

Investor verification priorities

  1. Confirm the filing’s company identity: the provided metadata names Chronoscale Holdings Corp., but the filing identifies PN Med Group Inc.
  2. Reconcile the nine-month net loss discrepancy: $7,924 in the statements versus $7,929 in MD&A.
  3. Check the cash-flow discussion against the statement: MD&A cites operating cash flow figures that do not match the statement’s nine-month use of $11,674.
  4. Verify the stated share-count date: the cover page says 5,950,000 shares were outstanding as of January 31, 2012, which conflicts with the company’s January 30, 2012 inception and the later-dated share disclosures.
  5. Assess the ability to fund operations, the demand repayment terms of shareholder loans, and the risk of dilution or unavailable financing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.